Compare Wockhardt with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs AUROBINDO PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT AUROBINDO PHARMA WOCKHARDT/
AUROBINDO PHARMA
 
P/E (TTM) x -20.1 11.0 - View Chart
P/BV x 1.1 2.4 44.4% View Chart
Dividend Yield % 0.0 0.5 0.7%  

Financials

 WOCKHARDT   AUROBINDO PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
AUROBINDO PHARMA
Mar-18
WOCKHARDT/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,012809 125.1%   
Low Rs532504 105.5%   
Sales per share (Unadj.) Rs355.9281.1 126.6%  
Earnings per share (Unadj.) Rs-60.341.4 -145.8%  
Cash flow per share (Unadj.) Rs-46.850.9 -91.9%  
Dividends per share (Unadj.) Rs0.012.50 0.4%  
Dividend yield (eoy) %00.4 0.3%  
Book value per share (Unadj.) Rs257.8199.4 129.3%  
Shares outstanding (eoy) m110.63585.88 18.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.3 92.8%   
Avg P/E ratio x-12.815.9 -80.7%  
P/CF ratio (eoy) x-16.512.9 -127.9%  
Price / Book Value ratio x3.03.3 90.9%  
Dividend payout %06.0 -0.3%   
Avg Mkt Cap Rs m85,379384,630 22.2%   
No. of employees `0006.317.3 36.1%   
Total wages/salary Rs m9,37121,308 44.0%   
Avg. sales/employee Rs Th6,295.09,500.7 66.3%   
Avg. wages/employee Rs Th1,498.31,229.4 121.9%   
Avg. net profit/employee Rs Th-1,066.31,397.9 -76.3%   
INCOME DATA
Net Sales Rs m39,369164,666 23.9%  
Other income Rs m1,2021,020 117.9%   
Total revenues Rs m40,571165,686 24.5%   
Gross profit Rs m1837,718 0.0%  
Depreciation Rs m1,4955,580 26.8%   
Interest Rs m2,555777 328.7%   
Profit before tax Rs m-2,83032,380 -8.7%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2578,183 3.1%   
Profit after tax Rs m-6,66924,229 -27.5%  
Gross profit margin %022.9 0.2%  
Effective tax rate %-9.125.3 -35.9%   
Net profit margin %-16.914.7 -115.1%  
BALANCE SHEET DATA
Current assets Rs m33,796121,878 27.7%   
Current liabilities Rs m26,91786,806 31.0%   
Net working cap to sales %17.521.3 82.0%  
Current ratio x1.31.4 89.4%  
Inventory Days Days79130 61.1%  
Debtors Days Days8968 130.5%  
Net fixed assets Rs m39,66481,037 48.9%   
Share capital Rs m553586 94.4%   
"Free" reserves Rs m27,968116,218 24.1%   
Net worth Rs m28,522116,804 24.4%   
Long term debt Rs m21,7314,512 481.6%   
Total assets Rs m81,620211,052 38.7%  
Interest coverage x-0.142.7 -0.3%   
Debt to equity ratio x0.80 1,972.4%  
Sales to assets ratio x0.50.8 61.8%   
Return on assets %-5.011.8 -42.5%  
Return on equity %-23.420.7 -112.7%  
Return on capital %-7.727.4 -28.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80780,727 12.1%   
Fx outflow Rs m1,78934,700 5.2%   
Net fx Rs m8,01946,027 17.4%   
CASH FLOW
From Operations Rs m68419,548 3.5%  
From Investments Rs m6,302-19,570 -32.2%  
From Financial Activity Rs m-7,6958,642 -89.0%  
Net Cashflow Rs m-6648,922 -7.4%  

Share Holding

Indian Promoters % 74.5 54.1 137.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 8.0 28.9%  
FIIs % 7.7 27.7 27.8%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.2 151.0%  
Shareholders   67,757 69,601 97.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare WOCKHARDT With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Oct 22, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - STERLING BIOTECH COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS